Member Info for dallo

Nolupus

10 year change of auditor mandatory for UK Public companies.

New auditor appointed with immediate effect doesn't really mean anything as the audit will not start until April/May 2024 .

It is what Auditors describe as a "small audit" meaning not much fees in it.

The appointment of Ms Clarke as full time CFO meant that no ancillary outsourcing fees are available for the ongoing Accounting/Auditing firm so probably not worth it's while.

A public company has to be careful with the wording of a change of Auditor so as not to mention such matters as lower fees and less work et al.

The appointment of the new Auditors will be ratified /approved at the 2025 AGM....I hope we are all still around at that stage!!!

With analysts forecasting peak LYT-100 sales of $800m per annum on a successful Phase 3 and commercial launch , a potential valuation of c $1.5b to $2b for LYT-100 appears reasonable.

Throw in everything else in Puretech from current cash, future royalties from BMS , Seaport and Gallop plus Vedanta et al , and you have a potentially $3/4b enterprise in perhaps 2 years or so.

But Mr Market just yawns .

However Puretech is now more vulnerable to a bid than ever before imho.

ATB

JSB

Like everyone invested in Puretech, I am shocked by the share price reaction to the very positive LYT 100 news.

Utterly incredible.

The SP in the US Is up 23% pre market at $25.

Oldernowiser

Looks like more bad news from McCarthy with SP at 1p...terrible

Buyers coming in now.

A case of dump and pump?

Pokerchips

Looks like a Lanstead dump but buyers coming in at the low levels of the day.

Biggest volume day in Immupharma for many many months .

I hope we are not going to get a bad news RNS despite what IR is telling us.

ATB

Wildbunch

Thanks for cheering us up

If you make a small fortune, I will make a large fortune!.

Keep the faith as the market cap is a joke.

ATB

Nolupus

Lack of news on trials and deals is killing confidence and wrecking the share price.

Maybe Tim will get back to working for Immupharma now that Incanthera is toast.

On second thoughts maybe he should stay away from Immupharma with his current run of luck!!

Nolupus

A disastrous situation in Incanthera and Mc Carthy must be sick with his dreams of rich pickings gone .

So Immupharma's financial asset in Incanthera is worthless now so the importance and urgency of commercial deals are paramount if Immupharma is not to be forced back to begging from the backstreet money lender.

The £75k paid to extend the warrants in Incanthera seems very expensive now but it could have been a whole worse if we had taken them up..ouch!

For what it is worth, Immupharma with a market cap of just £6m , is valued at its deferred tax losses forward of c £60m plus its listing.

The market has discounted its P140 drug programmes as worthless .

So any newsflow from Immupharma to the contrary could transform the landscape and propel the SP higher.

Of course I have been saying this for 6 months now !

JSB

Good spot

Long time waiting but nice to see a bounce off multi year lows

It could surge from here.

JSB

Moving now

Suddenly strong buying

LYT-100 news imminent ??

GoldGirl

At 10.58 am the bid dropped to 1.4p and the offer was at 1.5p and then a flurry of trades of 6m in total hit the

screens driving the offer back to 1.6p and the bid at 1.57p.

Very unusual activity with perhaps Lanstead offloading against strong buying interest.

Who knows but surely some form of update is due shortly.

Let's see what the afternoon brings.

Total volume now at 7m shares dealt which is a spike from the lacklustre norm of the past 6 months or so.

Draye

GSK has bought a biospecific drug therapy from Chimagen Biosciences , a Chinese Pharma based in Shanghai , for $300m.

The drugs have potential to treat a number of autoimmune diseases particularly Lupus.

GSK intends to commence a Phase 1 trial in 2025 for Lupus based on the acquired therapies.

The big question we are all asking as Immupharma investors is how come Immupharma is valued at a paltry £6m with Lupuzor about to enter a Phase 3 trial for Lupus and a Phase 2 /3 trial for CIPD in the offing.

Surely our P140 therapies are worth considerably more than the market is currently valuing them at.

Perplexing indeed

Jen

Abysmal investors communications.

Now 1.60p bid and no support.

Sad.

Wave of selling just appeared.

Down 8%

Could get worse by the look of Level2

Leas

What I have learnt in my long life is what you get and what you think you deserve are two totally different things.

Cheers

ATB

Leas

I meant the SP could quickly reach 5p or so following newsflow on Lupuzor trial/ Commercial deals.

Obviously Immupharma would be more interesting to investors as trial(s) progress and its funding secure for the next few years

The funding issue can be resolved through successful commercial deals upfront payments, 2p warrants exercised and/or Incanthera warrants exercised at a profit.

ATB

Wigwammer

Fair points indeed.

My original investment in Immupharma was a small punt on the Phase 3 trial which took a long time before we got news of its failure.

I have added on the Avion deal, the announcement of the new Lupuzor trial and the CIPD developments et al.

While I now have a large shareholding my breakeven is

much lower at 5p ish.

If the company can deliver then 4/5p is achievable in the short-term imho

I am hoping that the Lupuzor trial will start and commercial deals will be signed on Lupuzor/ CIPD.

Also Immupharma is surely worth more than the current market to a potential acquirer given its c £50m in deferred tax losses and late stage drug portfolio allied to no debt and its listing.

We shall see.